Anti-FGFR2b Antibody Monotherapy for Solid Tumor Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective monotherapies for certain types of solid cancers that overexpress FGFR2, such as squamous cancer, triple-negative breast cancer, intrahepatic cholangiocarcinoma, and gynecological malignancies, as current treatments often involve multiple modalities and lack targeted therapies.
Innovation Solution
Administering an anti-FGFR2b antibody monotherapy, such as bemarituzumab, in specific dosing regimens to target and inhibit FGFR2b signaling in these cancers, including Q2W regimens with varying doses and additional single administrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple modalities of treatment are used, then treatment coverage is improved, but treatment complexity increases
Solution Approach 1:
The patent extracts and isolates the FGFR2b signaling pathway as a specific target within the complex cancer treatment landscape. By identifying and blocking this specific pathway with anti-FGFR2b antibodies, the invention simplifies treatment focus while maintaining effectiveness against FGFR2b-overexpressing tumors, resolving the contradiction between comprehensive coverage and treatment simplicity.
2Measurement precision
If targeted therapy is developed, then treatment precision is improved, but therapeutic options are reduced
Solution Approach 1:
The invention applies local quality by targeting specifically the FGFR2b receptor subtype found in certain cancer types rather than using broad-spectrum therapies. The anti-FGFR2b antibody therapy provides precise treatment for FGFR2b-overexpressing tumors while maintaining optionality through different dosing regimens (Q2W and Q4W), thus achieving both precision and therapeutic versatility.
3Ease of operation
If conventional therapies are used, then treatment accessibility is improved, but treatment effectiveness decreases
Solution Approach 1:
The patent employs parameter changes by establishing specific dosing regimens (Q2W: 20-30 mg/kg first dose followed by 12-20 mg/kg; Q4W: 10-20 mg/kg) that optimize the balance between accessibility and effectiveness. These standardized dosing parameters make the therapy readily implementable while achieving superior effectiveness compared to conventional therapies for FGFR2b-positive cancers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-FGFR2b antibody therapy effectively inhibits tumor growth and enhances immune response, providing targeted treatment options for FGFR2b-overexpressing solid tumors, particularly after conventional therapies.
Implementation Method 1
administering an anti-FGFR2b antibody monotherapy... to target and inhibit FGFR2b signaling
Implementation Method 2
The anti-FGFR2b antibody therapy effectively inhibits tumor growth and enhances immune response
Data Source
AI summary
Methods of treating solid tumors, such as squamous cancer (such as head and neck squamous cell carcinoma), ER− PR− HER2/neu− (“triple-negative”) breast cancer, intrahepatic cholangiocarcinoma, lung adenocarcinoma, and gynecological malignancy, in subjects are described. The methods may comprise administering an anti-FGFR2b antibody to the subject.